(19)
(11) EP 2 270 045 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
25.02.2015 Bulletin 2015/09

(45) Mention of the grant of the patent:
31.12.2014 Bulletin 2015/01

(21) Application number: 10010733.3

(22) Date of filing: 04.02.2005
(51) International Patent Classification (IPC): 
C07K 16/12(2006.01)
A61P 1/00(2006.01)
C12N 15/13(2006.01)
C12N 1/15(2006.01)
A61K 47/48(2006.01)
A61P 31/04(2006.01)
 A61P 1/12(2006.01)
A61K 39/395(2006.01)
C12N 1/21(2006.01)
C12N 5/10(2006.01)
A61K 39/08(2006.01)

(54)

Antibodies against Clostridium difficile toxins and uses thereof

Antikörper gegen Clostridium difficile Toxine und ihre Verwendung

Anticorps contre les toxines de Clostridium difficile et ses utilisations

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

(30) Priority: 06.02.2004 US 542357 P
28.09.2004 US 613854 P

(43) Date of publication of application:
05.01.2011 Bulletin 2011/01

(60) Divisional application:
14194551.9

(62) Application number of the earlier application in accordance with Art. 76 EPC:
05857759.4 / 1766093

(73) Proprietors:
  • University of Massachusetts
    Boston, MA 02108 (US)
  • E. R. Squibb & Sons, L.L.C.
    Princeton, NJ 08540 (US)

(72) Inventors:
  • Ambrosino, Donna
    Jamaica Plain, MA 02130 (US)
  • Babcock, Gregory J.
    Marlborough, MA 01752 (US)
  • Broering, Theresa
    Brookline, MA 02446 (US)
  • Graziano, Robert
    Frenchtown, NJ 08825 (US)
  • Hernandez, Hector Javier
    Canton, MA 02021 (US)
  • Lowy, Israel
    Dobbs Ferry, NY 10522 (US)
  • Mandell, Robert
    Collins, Iowa 50055 (US)
  • Molrine, Deborah
    Newton, MA 02461 (US)
  • Thomas, William D.
    Dedham, MA 02026 (US)
  • Zhang, Hui-fen
    Bridgewater, MA 08807 (US)

(74) Representative: Woods, Geoffrey Corlett 
J A Kemp 14 South Square Gray's Inn
London WC1R 5JJ
London WC1R 5JJ (GB)


(56) References cited: : 
WO-A1-93/12232
WO-A2-03/079750
 WO-A2-01/53353
   
  • DENG XIAO K ET AL: "Recombinant single-chain variable fragment antibodies directed against Clostridium difficile toxin B produced by use of an optimized phage display system." CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY. JUL 2003, vol. 10, no. 4, July 2003 (2003-07), pages 587-595, XP002407792 ISSN: 1071-412X
  • GENTH H ET AL: "New method to generate enzymatically deficient Clostridium difficile toxin B as an antigen for immunization." INFECTION AND IMMUNITY MAR 2000 LNKD- PUBMED:10678912, vol. 68, no. 3, March 2000 (2000-03), pages 1094-1101, XP002608530 ISSN: 0019-9567
  • CORTHIER G ET AL: "PROTECTION AGAINST EXPERIMENTAL PSEUDOMEMBRANOUS COLITIS IN GNOTOBIOTIC MICE BY USE OF MONOCLONAL ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXIN A" INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 59, no. 3, 1 March 1991 (1991-03-01), pages 1192-1195, XP002912253 ISSN: 0019-9567
  • KINK J A ET AL: "ANTIBODIES TO RECOMBINANT CLOSTRIDIUM DIFFICILE TOXINS A AND B ARE EFFECTIVE TREATMENT AND PREVENT RELAPSE OF C. DIFFICILE-ASSOCIATED DISEASE IN A HAMSTER MODEL OF INFECTION" INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 66, no. 5, 1 May 1998 (1998-05-01), pages 2018-2025, XP002912254 ISSN: 0019-9567
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).